4565 On Other Exchanges
4565 is not on other exchanges.

sosei group corp (4565) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOSEI GROUP CORP (4565)

Related News

No related news articles were found.

sosei group corp (4565) Related Businessweek News

No Related Businessweek News Found

sosei group corp (4565) Details

Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD); Ultibro/QVA149, an inhalation capsule for the bronchodilator treatment of COPD; and NorLevo, an oral emergency contraceptive. The company’s product pipeline consists of SO-1105, an antifungal agent, which is in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious eye diseases, such as cornea and conjunctivitis, and inflammation. In addition, it develops JIT-2001 for cardiovascular disease and JIT-1007 for rare diseases that are in pre-clinical stage. Further, the company is developing product candidates, which are in Phase I clinical trial for the treatment of Alzheimer's, schizophrenia, and cancer immuno-oncology diseases; and in preclinical trail for the treatment of psychosis and cognitive impairment in Alzheimer's, schizophrenia, mental illness, and other diseases, as well as migraine, prophylaxis, and neurological and psychiatric disorders. Sosei Group Corporation was founded in 1990 and is headquartered in Tokyo, Japan.

116 Employees
Last Reported Date: 06/27/16
Founded in 1990

sosei group corp (4565) Top Compensated Officers

Founder, Executive Chairman, Representative E...
Total Annual Compensation: ¥181.0M
Compensation as of Fiscal Year 2016.
sosei group corp
Sosei Group Corporation Announces Executive Changes

Sosei Group Corporation announced the appointment of Andrew Oakley as Chief Financial Officer effective from February 1 2017. Mr. Oakley will be based in Sosei's Tokyo offices. Mr. Oakley will succeed Mr. Hidetoshi Torami who has resigned from Sosei for personal reasons. Mr. Oakley had a wide and varied financial career and over the past 14 years has held CFO positions in several publicly listed biotechnology companies including Actelion Ltd, Novimmune SA, and most recently at Vectura Group plc, where he was also a member of the Board.

Sosei Group Corporation, Q2 2017 Earnings Call, Nov 14, 2016

Sosei Group Corporation, Q2 2017 Earnings Call, Nov 14, 2016

Sosei Group Corporation Reports Consolidated Earnings Results for the Six Months Quarter Ended September 30, 2016; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2017

Sosei Group Corporation reported consolidated earnings results for the six months quarter ended September 30, 2016. The group reported revenue of JPY 15,839 million against JPY 2,540 million a year ago. Operating income was JPY 12,223 million against loss of JPY 753 million a year ago. Net income before tax of income taxes was JPY 13,245 million against net loss before tax of income taxes of JPY 1,418 million a year ago. Net income was JPY 10,592 million against net loss of JPY 1,175 million a year ago. Net income attributable to owners of the parent company was JPY 10,716 million against net loss attributable to owners of the parent company of JPY 1,128 million a year ago. Net income per diluted share was JPY 631.75 against net loss per diluted share of JPY 80.71 million a year ago. Net cash from operating activities was JPY 12,557 million against JPY 1,650 million a year ago. Purchases of property, plant and equipment was JPY 110 million against JPY 70 million a year ago. For the fiscal year ending March 31, 2017, the company expects revenue of JPY 27,925 million, operating income of JPY 17,096 million, net income before income taxes of JPY 14,901 million, net income attributable to owners of parent of JPY 13,064 million and net basic earnings per share of JPY 775.07.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4565 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4565.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4565 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SOSEI GROUP CORP, please visit www.sosei.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.